Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464448 · ClinicalTrials.gov registry record
Mechanistic Studies of Teriflunomide in RRMS
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 30
- Enrollment target
NCT03464448 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 30 participants.
The verdict
NCT03464448 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study is to address the mechanism of action of teriflunomide in a phase IV open label trial with Teriflunomide in multiple sclerosis. Researchers will recruit 20 relapsing remitting multiple sclerosis patients (Group 1) start on treatment with teriflunomide (Aubagio). Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. Meanwhile, 10 healthy controls will be recruited, to establish a healthy baseline for B and T cells, which are affected by both MS and its treatment (Group 2). This Study will collect baseline pre-treatment blood samples periodically for up to 2 years. Blood biomarker changes will be correlated with clinical response to teriflunomide treatment intervention.
Interventions
- DRUG Teriflunomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2021-10-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03464448
The ClinicalTrials.gov registry entry for NCT03464448 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Teriflunomide is the first listed.
NCT03464448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03464448 about?
NCT03464448 is a clinical study titled "Mechanistic Studies of Teriflunomide in RRMS". This study is to address the mechanism of action of teriflunomide in a phase IV open label trial with Teriflunomide in multiple sclerosis. Researchers will recruit 20 relapsing remitting multiple sclerosis patients (Group 1) start on treatment with teriflunomide (Aubagio). Patients will be enrolled ...
What is the current status of trial NCT03464448?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-04-17. Estimated completion is 2021-10-13.
What interventions are being tested in trial NCT03464448?
The interventions under investigation include: Teriflunomide (DRUG).
Who is sponsoring clinical trial NCT03464448?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.